-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

Benzinga·05/11/2026 11:24:26
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.